Evidence map›Paper›PMID 40998256›Full record

ArticleJournal of advanced research2026

Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.

Xuexiao Li, Binyan Zhong, Nan Jiang, Jintao Huang, Di Hu, Ruoran Zhou, Jianfeng Zeng, Wenmiao Shu, Guangxin Duan, Shuwang Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xuexiao LiDepartment of Radiology, Affiliated Hangzhou First People's Hospital , School of Medicine, Westlake University, Hangzhou 310006, China; State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Binyan ZhongDepartment of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Nan JiangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215123, China.
Jintao HuangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215123, China.
Di HuDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215123, China.
Ruoran ZhouState Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Jianfeng ZengState Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Wenmiao ShuDepartment of Biomedical Engineering, University of Strathclyde, Glasgow G4 0NW, UK.
Guangxin DuanState Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China. Electronic address: gxduan@suda.edu.cn.
Shuwang WuState Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China. Electronic address: wushuwang@suda.edu.cn.
Ling WenDepartment of Radiology, The Fourth Affiliated Hospital of Soochow University, Medical Centre of Soochow University, Suzhou 215000, China; State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China. Electronic address: wenling@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTransarterial radioembolization (TARE) is a highly effective treatment for unresectable hepatocellular carcinoma (HCC). However, current clinically available radioactive

objectivesTo address these challenges, we propose a novel diphosphonate based hydrogel microspheres (DPMs) for safer and more effective TARE therapies. The diphosphonate have a strong chelating capability with various metal ions which provide a universal strategy for tightly labelling the hydrogel microsphere with different therapeutic metal nuclides.

methodsIn this study, DPMs were fabricated via microfluidic technology, followed by

resultsDPMs achieved a labeling efficiency of 98.3 % within 15 min. Meanwhile, the radiolabeling rate maintained 99 % over 7 days in a 10 % fetal bovine serum solution, demonstrating exceptional radiostabilty. The high in vitro radiostability is also consistent with in vivo experiments. Additionally, the porous structure of DPMs enables high loading and controlled release of chemotherapeutic drugs, making the hydrogel microspheres also the ideal carriers for transcatheter arterial chemoembolization (TACE). By combining TARE and TACE, we have developed a novel

conclusionThis study introduces a groundbreaking approach using highly effective diphosphonate based microspheres to deliver precise, safe, and powerful treatment for unresectable HCC and other challenging tumors.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticDiphosphatesHydrogelsLiver NeoplasmsMicrospheresRadioembolization, TherapeuticAnimalsCell Line, TumorDoxorubicinHumansLutetiumRabbitsRadioisotopesDiphosphatesDoxorubicinHydrogelsLutetiumRadioisotopes(177)Lu labelingDiphosphateHepatocellular carcinomaHydrogel microspheresRadioembolization

Identifiers

PMID40998256
PMCPMC13227269

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.